Clinical Trials
42 trialsChemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Roswell Park Cancer Institute
Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant
M.D. Anderson Cancer Center
Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell
Stanford University
Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II
M.D. Anderson Cancer Center
CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
Columbia University
Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies
Indiana University
Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies
M.D. Anderson Cancer Center
Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML
M.D. Anderson Cancer Center
DC Vaccination in CML
Charite University, Berlin, Germany
A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML
University of Michigan Rogel Cancer Center
Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia
University Health Network, Toronto
An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)
M.D. Anderson Cancer Center
Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin
M.D. Anderson Cancer Center
IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT
Masonic Cancer Center, University of Minnesota
Cord Blood
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer
Fred Hutchinson Cancer Center
Safety and Feasibility of the Use of Natural Killer Cells in Patients With Chronic Myeloid Leukemia
Hospital de Clinicas de Porto Alegre
Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells
Stanford University
Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation
Milton S. Hershey Medical Center
Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML
Fred Hutchinson Cancer Center
Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies
Washington University School of Medicine
alloCIK
Singapore General Hospital
Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)
Baylor College of Medicine
CML2004
University of Leipzig
RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.
University of Michigan Rogel Cancer Center
ALLO-WT1
Institut Paoli-Calmettes
Prevention of Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Receiving a Bone Marrow Transplant
Fred Hutchinson Cancer Center
Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
B-cell therapy
University of Erlangen-Nürnberg Medical School
Prophylactic Transfer of Leukemia-reactive T Cells After Allogeneic Transplantation
University Hospital Carl Gustav Carus
Bendamustine in Acute Leukemia and MDS
M.D. Anderson Cancer Center
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia
Columbia University
Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases
Baylor College of Medicine
Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
OHSU Knight Cancer Institute
Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic Malignancies
Keio University
PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP
M.D. Anderson Cancer Center
Imatinib Mesylate After a Donor Stem Cell Transplant in Treating Patients With Philadelphia Chromosome-Positive Leukemia
Fred Hutchinson Cancer Center
Allogeneic Tumor Cell Vaccination in Patients With Chronic Myeloid Leukemia
Hadassah Medical Organization
Fludarabine, Total-Body Irradiation, and Donor Stem Cell Transplant Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Chronic Myelogenous Leukemia
Fred Hutchinson Cancer Center
Safety and Efficacy of Imatinib in Combination With High Dose Chemotherapy for Acute Phase Chronic Myelogenous Patients
Poitiers University Hospital